Investigation of the Dissolution Characteristics of Nifedipine Extended-Release Formulations Using USP Apparatus 2 and a Novel Dissolution Apparatus

The aim of our studies was to investigate the dissolution characteristics of six extended-release nifedipine tablets with a dosage strength of 20 mg that are marketed in the European Union. All investigated products were homogenous matrix tablets having identical dosing regimens. The products can be substituted for originator products and other ER generic formulations of the same drug load. In the present study, the formulations were tested using USP Apparatus 2 at 50 rpm, which is one of the standard conditions specified by the USP for nifedipine ER tablets. Moreover, investigations under intensified stress conditions were performed with Apparatus 2 at 100 rpm, as well as in a novel biorelevant dissolution stress-test device. A complementary characterization of the integrity of the tablet matrices was performed using a standard disintegration test apparatus. In the applied experimental settings, drug dissolution from all tested formulations proceeded very fast with liberation of at least 15 mg of drug within the first two hours of analysis. The increase in stirring rate from 50 to 100 rpm in Apparatus 2 did not substantially accelerate the dissolution process. Moreover, it was noticed that the tablet matrices had poor mechanical stability and very rapid disintegration behavior under all experimental settings. The disintegration times measured in the standard disintegration test were less than 10 min. The results clearly show that the dissolution characteristics of all tested products are a function of the properties of the drug substance and not the dosage forms. It became obvious that none of the tested formulations fulfilled USP requirements for nifedipine ER tablets specified for Apparatus 2 at 50 rpm. However, the products are marketed in the European Union where the USP quality criteria are not mandatory but only advisable. In our interpretation, such dissolution characteristics bear a potential risk of dosage-form-related interactions in vivo.

[1]  C. Toal.  Formulation Dependent Pharmacokinetics—Does the Dosage Form Matter for Nifedipine? , 2004, Journal of cardiovascular pharmacology.

[2]  P A Meredith,et al.  Nifedipine: Individual Responses and Concentration‐Effect Relationships , 1988, Hypertension.

[3]  L. Marciani,et al.  Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[4]  E. Brendel,et al.  Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. , 2008, Clinical Therapeutics.

[5]  P. Corvol,et al.  Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine , 2004, European Journal of Clinical Pharmacology.

[6]  P. Meredith,et al.  Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. , 2004, Journal of hypertension.

[7]  T. Walley,et al.  Acute inotropic effects of intravenous nifedipine and its vehicle compared with saline: a double-blind study of systolic time intervals in normal subjects. , 1988, British journal of clinical pharmacology.

[8]  J. Dressman,et al.  Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.

[9]  J. Dressman,et al.  Influence of Hydrodynamics and Particle Size on the Absorption of Felodipine in Labradors , 2004, Pharmaceutical Research.

[10]  T. Walley,et al.  Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers. , 1987, British journal of clinical pharmacology.

[11]  S. Sarna,et al.  Central regulation of gastric emptying of solid nutrient meals by corticotropin releasing factor , 1997, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  U. Fuhr,et al.  Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine , 1996, European Journal of Clinical Pharmacology.

[13]  A. Renwick,et al.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. , 1988, British journal of clinical pharmacology.

[14]  J. M. McCarthy,et al.  Dog Colonoscopy Model for Predicting Human Colon Absorption , 2006, Pharmaceutical Research.

[15]  E. Brendel,et al.  Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  R. Schall,et al.  The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. , 2002, British journal of clinical pharmacology.

[17]  S. Qureshi,et al.  Applications of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[19]  M. A. Matlib,et al.  Pharmacology of calcium antagonists. , 1985, The American journal of cardiology.

[20]  N. Hosten,et al.  Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.

[21]  D. Breimer,et al.  Nifedipine: Kinetics and dynamics in healthy subjects , 1984, Clinical pharmacology and therapeutics.

[22]  H. Schoemaker,et al.  Intraindividual Variability in Nifedipine Pharmacokinetics and Effects in Healthy Subjects , 1992, Journal of clinical pharmacology.

[23]  Clive G. Wilson,et al.  Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.